EMBRACE - Early detection of Brain Cancer using a novel spectroscopic liquid biopsy enabling timely detection and diagnosis for patient benefit

Dxcover是一家临床阶段诊断公司，致力于为临床提供创新的早期癌症诊断。利用我们的平台技术，我们将提供世界上第一个改变游戏规则的脑癌检测血液测试(Dxcover Brain)，它将无缝地融入当前的护理标准路径。脑癌平均会减少20多年的预期寿命，这一统计数据在很大程度上归因于它的较晚发现。诊断途径效率很低，因为目前只有~2%的转诊为成像的患者实际上患有脑癌。Dxcover的独特技术使用红外线来检测来自肿瘤的信号以及人体对肿瘤的反应信号。目前已在多项临床研究的3000个患者样本中得到验证，我们为癌症早期检测提供了简单的工作流程和快速且负担得起的解决方案。EIC资金将使Dxcover能够获得CE-IVDR批准，瞄准欧洲市场，更快地接触到患者。

Dxcover is a clinical stage diagnostics company, dedicated to delivering innovative early cancer diagnostics to the clinic. Using our platform technology, we will provide the world’s first game-changing blood test for brain cancer detection (Dxcover Brain) that fits seamlessly into current standard-of-care pathway. Brain cancer reduces life expectancy by over 20 years on average, a statistic that is largely attributed to its late detection. The diagnostic pathway is highly inefficient, as currently only ~2% of patients referred for imaging actually have brain cancer. Dxcover’s unique technology uses infrared light to detect signals from the tumour and signals from the body’s response to the tumour. Currently validated in >3000 patient samples across multiple clinical studies, we provides a simple workflow, and a fast and affordable solution for early cancer detection. EIC funding will allow Dxcover to obtain CE-IVDR approval, target the European market and reach the patient faster.